Crinetics Pharmaceuticals (CRNX) News Today $56.06 -0.97 (-1.70%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Promising Outlook for Crinetics Pharmaceuticals’ Paltusotine in Phase 3 Trial Drives Buy RatingNovember 23 at 3:13 PM | markets.businessinsider.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stake Reduced by BNP PARIBAS ASSET MANAGEMENT Holding S.A.BNP PARIBAS ASSET MANAGEMENT Holding S.A. lessened its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 10.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 491,381 shares of the company's stock after selling 54,853 shares durNovember 23 at 4:59 AM | marketbeat.comPrincipal Financial Group Inc. Acquires 64,504 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Principal Financial Group Inc. raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 488.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 77,709 shares of the company's stockNovember 22 at 3:08 AM | marketbeat.comJennison Associates LLC Acquires 13,470 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Jennison Associates LLC boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 0.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,793,614 shares of the company's stock after purchasing an aNovember 20, 2024 | marketbeat.comVictory Capital Management Inc. Purchases 116,657 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Victory Capital Management Inc. increased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 51.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 343,344 shares of the company's stocNovember 20, 2024 | marketbeat.comFirst Turn Management LLC Sells 15,926 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)First Turn Management LLC lessened its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 4.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 353,376 shares of the company's stock after selNovember 19, 2024 | marketbeat.comCRNX FY2024 EPS Estimate Increased by Cantor FitzgeraldNovember 19, 2024 | americanbankingnews.comWhat is Leerink Partnrs' Estimate for CRNX FY2024 Earnings?November 18, 2024 | americanbankingnews.comFY2024 EPS Estimates for CRNX Increased by Cantor FitzgeraldCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for Crinetics Pharmaceuticals in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company willNovember 18, 2024 | marketbeat.comLeerink Partnrs Has Strong Forecast for CRNX FY2024 EarningsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Leerink Partnrs boosted their FY2024 EPS estimates for shares of Crinetics Pharmaceuticals in a report issued on Wednesday, November 13th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per sharNovember 18, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CRNX FY2024 Earnings?November 16, 2024 | americanbankingnews.comCrinetics Pharmaceuticals to Participate in Three Upcoming December Investor ConferencesNovember 15, 2024 | markets.businessinsider.comHC Wainwright Issues Pessimistic Forecast for CRNX EarningsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for Crinetics Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst D. Tsao now expects that the company willNovember 15, 2024 | marketbeat.comFY2024 Earnings Forecast for CRNX Issued By Lifesci CapitalCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Stock analysts at Lifesci Capital lowered their FY2024 earnings per share estimates for shares of Crinetics Pharmaceuticals in a report issued on Tuesday, November 12th. Lifesci Capital analyst C. Jubinville now expects that the companNovember 15, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 1-Year High Following Analyst UpgradeNovember 15, 2024 | americanbankingnews.comUPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual MeetingNovember 14, 2024 | globenewswire.comCrinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 14, 2024 | tmcnet.comCrinetics Pharmaceuticals: Promising Future with Innovative Drug Developments and Strong Financial PositionNovember 14, 2024 | markets.businessinsider.comPositive Outlook for Crinetics Pharmaceuticals: Strategic Advancements and Strong Financial Position Drive Target Price IncreaseNovember 14, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Moderate Buy" by BrokeragesNovember 14, 2024 | americanbankingnews.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by AnalystsShares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eleven brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and ten have assNovember 14, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPSCrinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.05). During the same period last year, the firm posted ($1.01) EPS.November 13, 2024 | marketbeat.comCrinetics Pharmaceuticals: Advancing Cancer Treatment with Novel NDC Platform – A Buy RecommendationNovember 13, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals Announces Q3 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...November 13, 2024 | finance.yahoo.comCrinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comCrinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual MeetingNovember 12, 2024 | globenewswire.comCrinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comCrinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 12, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 11, 2024 | globenewswire.comLisanti Capital Growth LLC Purchases 25,195 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Lisanti Capital Growth LLC lifted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 30.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 108,575 shares of the company's stock after purchasing an additional 25,195 sharNovember 11, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Fiera Capital CorpFiera Capital Corp decreased its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 3.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 466,075 shares of the company's stock after selling 14,334 shares duNovember 9, 2024 | marketbeat.comCrinetics Pharmaceuticals (CRNX) to Release Earnings on TuesdayCrinetics Pharmaceuticals (NASDAQ:CRNX) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=636105)November 5, 2024 | marketbeat.comabrdn plc Cuts Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)abrdn plc reduced its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 46.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,467 shares of the company's stock after sellinNovember 5, 2024 | marketbeat.comInvestors might be losing patience for Crinetics Pharmaceuticals' (NASDAQ:CRNX) increasing losses, as stock sheds 5.6% over the past weekOctober 30, 2024 | finance.yahoo.comCrinetics Pharmaceuticals: Strong Buy Recommendation Driven by Best-in-Class Efficacy and Solid Financial PositionOctober 24, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Position Cut by Moody Aldrich Partners LLCMoody Aldrich Partners LLC trimmed its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 7.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 139,130 shares of the company'sOctober 24, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 1-Year High - Here's What HappenedCrinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 1-Year High - Time to Buy?October 22, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 1-Year High - Should You Buy?Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 12-Month High - What's Next?October 16, 2024 | marketbeat.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Shares Up 4.4% - Still a Buy?Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Up 4.4% - What's Next?October 15, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Sees Large Growth in Short InterestCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 6,780,000 shares, an increase of 11.0% from the September 15th total of 6,110,000 shares. Based on an average daily trading volume, of 655,400 shares, the short-interest ratio is currently 10.3 days.October 15, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Position Lowered by SG Americas Securities LLCSG Americas Securities LLC lowered its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 83.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,963 shares of the companyOctober 14, 2024 | marketbeat.comCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 12, 2024 | finanznachrichten.deCrinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 10, 2024 | globenewswire.comCrinetics Pharmaceuticals Selling Up to $460M in SharesOctober 10, 2024 | marketwatch.comCrinetics Pharma Prices Public Offering Of 10 Mln Shares At $50/ShrOctober 10, 2024 | markets.businessinsider.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Sees Large Volume Increase - Still a Buy?Crinetics Pharmaceuticals (NASDAQ:CRNX) Sees Large Volume Increase - Time to Buy?October 9, 2024 | marketbeat.comCrinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockOctober 8, 2024 | globenewswire.comCrinetics Pharmaceuticals Announces Proposed Public Offering of Common StockOctober 8, 2024 | globenewswire.comDana Pizzuti Sells 14,375 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) StockOctober 8, 2024 | insidertrades.com Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Coins Set to Soar with a Pro-Crypto White House (Ad)Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets… Click here to reserve your free seat at the Crypto Community Summit CRNX Media Mentions By Week CRNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRNX News Sentiment▼0.710.49▲Average Medical News Sentiment CRNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRNX Articles This Week▼166▲CRNX Articles Average Week Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ionis Pharmaceuticals News Today Avadel Pharmaceuticals News Today Bicycle Therapeutics News Today Teva Pharmaceutical Industries News Today BeiGene News Today Viatris News Today Moderna News Today Summit Therapeutics News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRNX) was last updated on 11/24/2024 by MarketBeat.com Staff From Our Partners[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
